The first variant-proof coronavirus booster vaccine is being trialed in Manchester in the UK.
Retired nurse Helen Clarke, 64, and her husband Andrew, 63, were the first to receive the new variant-proof GRT-R910 vaccine. The mRNA vaccine could eliminate the need for COVID-19 vaccines to be constantly updated to counter emerging strains of the disease.
Another 20 volunteers, all over the age of 60, constituting the most vulnerable cohort of the population will also receive the jab.
The research is being done through collaboration between US pharmaceutical company Gritstone, The University of Manchester, and Manchester University NHS Foundation Trust. The study will include identifying proper dosages, tolerability, immunogenicity, and side effects for over four months following initial administration. They hope for results by early 2022.
Retired nurse Helen Clarke, 64, and her husband Andrew, 63, were the first to receive the new variant-proof GRT-R910 vaccine. The mRNA vaccine could eliminate the need for COVID-19 vaccines to be constantly updated to counter emerging strains of the disease.
Another 20 volunteers, all over the age of 60, constituting the most vulnerable cohort of the population will also receive the jab.
The research is being done through collaboration between US pharmaceutical company Gritstone, The University of Manchester, and Manchester University NHS Foundation Trust. The study will include identifying proper dosages, tolerability, immunogenicity, and side effects for over four months following initial administration. They hope for results by early 2022.
